Teleflex Incorporated(TFX) Stock Research - Grey Stern Research
Loading...

Teleflex Incorporated (TFX) Stock Analysis

$239.38 (-1.87%)

TFX Financial Performance


Use the table below to view Teleflex Incorporated's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $243.93 -
52 Week Low $177.63 -
52 Week High $257.85 -
Market Cap $11.5 Billion 6/12
Gross Margin 56% 3/12
Profit Margin 11% 4/12
EBITDA margin 26% 4/12
Q2 - 2024 Revenue $749.7 Million 6/12
Q2 - 2024 Earnings $80.0 Million 7/12
Q2 - 2024 Free Cash Flow $56.5 Million 10/12
Trailing 4 Quarters Revenue $3.0 Billion 5/12
Trailing 4 Quarters Earnings $263.6 Million 7/12
Quarterly Earnings Growth -28% 8/12
Annual Earnings Growth -23% 9/12
Quarterly Revenue Growth 1% 9/12
Annual Revenue Growth 5% 4/12
Cash On Hand $238.6 Million 8/12
Short Term Debt $93.8 Million 5/12
Long Term Debt $1.6 Billion 4/12

Teleflex Incorporated Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Teleflex Incorporated's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 43.61 4/12
PS 3.82 6/12
PB 2.52 9/12
PC 48.18 4/12
Liabilities to Equity 0.63 8/12
ROA 0.04 7/12
ROE 0.06 7/12
Current Ratio 2.58 5/12
Quick Ratio 0.08 11/12
Long Term Debt to Equity 0.36 7/12
Debt to Equity 0.40 8/12
Burn Rate 28.51 2/12
Cash to Cap 0.02 8/12
CCR 0.71 7/12
EV to EBITDA 67.31 7/12
EV to Revenue 4.35 6/12

Company Details

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

CEO: Mr. Liam Kelly

Website: https://www.teleflex.com

Address: 550 E Swedesford Rd Ste 400 Wayne, PENNSYLVANIA

Exchange: New York Stock Exchange

Industry: Medical Instruments & Supplies

Teleflex Incorporated Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Teleflex Incorporated. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Becton, Dickinson and Company BDX $69.3 Billion
Hologic, Inc. HOLX $18.5 Billion
ResMed Inc. RMD $35.1 Billion
The Cooper Companies, Inc. COO $21.5 Billion
Haemonetics Corporation HAE $4.1 Billion
West Pharmaceutical Services, Inc. WST $21.7 Billion
Merit Medical Systems, Inc. MMSI $5.6 Billion
AngioDynamics, Inc. ANGO $310.9 Million
ICU Medical, Inc. ICUI $4.4 Billion
AptarGroup, Inc. ATR $10.5 Billion
Envista Holdings Corporation NVST $3.3 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
TFX Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 749.7 Million $80.0 Million
Q1 2024 $ 737.8 Million $15.3 Million
Q4 2023 $ 773.9 Million $31.1 Million
Q3 2023 $ 746.4 Million $137.1 Million
Q2 2023 $ 743.3 Million $111.3 Million
Q1 2023 $ 710.9 Million $76.7 Million
Q4 2022 $ 758.0 Million $78.6 Million
Q3 2022 $ 686.8 Million $101.9 Million

View All

TFX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $238.6 Million $7.4 Billion $1.8 Billion $4.6 Billion
Q1 2024 $237.4 Million $7.5 Billion $1.9 Billion $4.5 Billion
Q4 2023 $222.8 Million $7.5 Billion $1.9 Billion $4.4 Billion
Q3 2023 $881.5 Million $7.5 Billion $2.1 Billion $4.3 Billion
Q2 2023 $250.8 Million $6.9 Billion $1.7 Billion $4.2 Billion
Q1 2023 $264.1 Million $6.9 Billion $1.8 Billion $4.1 Billion
Q4 2022 $292.0 Million $6.9 Billion $1.8 Billion $4.0 Billion
Q3 2022 $397.3 Million $6.8 Billion $1.8 Billion $3.9 Billion

View All

TFX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $56.5 Million -$34.8 Million $1.1 Million
Q1 2024 $72.5 Million -$38.4 Million $14.6 Million
Q4 2023 $0 $0 $0
Q3 2023 $177.2 Million -$24.4 Million $630.7 Million
Q2 2023 $68.6 Million -$17.5 Million -$13.3 Million
Q1 2023 $62.2 Million -$21.8 Million -$27.9 Million
Q4 2022 $71.7 Million -$26.5 Million -$105.2 Million
Q3 2022 $122.6 Million -$20.2 Million $89.1 Million

View All